Ezetimibe monotherapy for cholesterol lowering in 2,722 people: Systematic review and meta-analysis of randomized controlled trials

Journal of Internal Medicine

Volumn 265, Issue 5, 2009, Pages 568-580

  Pandor, Abdullah ^a,b   Ara, R M ^a   Tumur, I ^a   Wilkinson, A J ^b   Paisley, S ^a   Duenas, A ^a   Durrington, P N ^c   Chilcott, J ^a  

^a Health Economics and Decision Science ^*  (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular diseases; Hypercholesterolaemia; LDL cholesterol; Meta analysis

Indexed keywords

CHOLESTEROL; EZETIMIBE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 64249120001     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02062.x     Document Type: Article

References (48)

1. Allender S, Peto V, Scarborough P, Boxer A, Rayner M. Coronary Heart Disease Statistics 2007 Edition. London : British Heart Foundation, 2007.
2. Peterson S, Peto V, Rayner M, Leal J, Luengo-Fernandez J, Gray A. European Cardiovascular Disease Statistics 2005 Edition. London : British Heart Foundation, 2005.
3. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl. 5 v1 52.
4. Isles CG, Paterson JR. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Q J Med 2000 93 : 567 74.
5. NHS Centre for Reviews and Dissemination. Cholesterol and coronary heart disease: screening and treatment. Eff Health Care Bull 1998 4 : 1 16.
6. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
7. Graham I, Atar D, Borch-Johnsen K et al. Fourth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007 194 : 1 45.
8. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004 24 : e149 61.
9. Ara R, Tumur I, Pandor A et al. Ezetimibe for the treatment of hypercholesterolaemia - a systematic review and economic evaluation. Health Technol Assess 2008 12 : 1 232.
10. NHS. Prescription cost analysis, England 2005. London : NHS Health and Social Care Information Centre, Health Care Statistics. 2006. Available from: http://www.ic.nhs.uk/pubs/prescostanalysis2005 (9 October 2006).
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 251 : 351 64.
12. Canner P, Furberg C, Terrin M, McGovern M. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005 95 : 254 7.
13. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 : 1849 61.
14. National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 132 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. London : NICE, 2007. Available from: http://www.nice.org.uk/nicemedia/pdf/TA132guidance.pdf (30th November 2007).
15. European Medicines Agency (EMEA). Committee for Medical Products for Human Use (CHMP) - note for guidance on clinical investigation of medical products in the treatment of lipid disorders. London : EMEA 2004. Available from: http://emea.europa.eu/pdfs/human/ewp/302003en.pdf (14th November 2006).
16. NHS Centre for reviews and Dissemination. Undertaking systematic reviews of research on effectiveness - CRD's guidance for those carrying out or commissioning reviews (Report 4). York : University of York, 2001.
17. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group Lancet 1997 350 : 185 6.
18. Clark HD, Wells GA, Huët C et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999 20 : 448 52.
19. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4. Chichester, UK : John Wiley & Sons, Ltd, 2006.
20. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003 107 : 2409 15.
21. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 26 : 1758 73.
22. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 40 : 2125 34.
23. Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1092 7.
24. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004 79 : 620 9.
25. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003 91 : 418 24.
26. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003 24 : 729 41.
27. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003 24 : 717 28.
28. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. Circulation 1991 83 : 356 62.
29. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992 152 : 1490 500.
30. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1423 7.
31. Gould AL, Rossouw JE, Santanello NC, Heyse J, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statins. Circulation 1998 97 : 946 52.
32. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005 46 : 1855 62.
33. Birjmohun RS, Hutten BA, Kastelein JP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005 45 : 185 97.
34. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007 154 : 943 53.
35. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 : 1431 3.
36. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 : 2109 22.
37. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 359 : 1343 56.
38. Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 359 : 1357 66.
39. Wierzbicki A. Lipid lowering, statins and cancer. Int J Clin Pract 2006 60 : 1022 4.
40. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med 2008 359 : 1400 2.
41. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003 4 : 18.
42. Joint Formulary Committee. British National Formulary. 52nd edn. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006.
43. Armitage J. The safety of statins in clinical practice. Lancet 2007 370 : 1781 90.
44. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005 165 (7 725 30.
45. Ara R, Pandor A, Tumur I et al. Cost-effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contra-indications - A markov model. Am J Cardiovasc Drugs (in press).
46. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983 309 : 1358 61.
47. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 273 : 408 12.
48. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 13.